Celgene Corp Fourth Quarter Earnings Sneak Peek
S&P 500 (NYSE:SPY) component Celgene Corporation (NASDAQ:CELG) will unveil its latest earnings on Thursday, January 26, 2012. Celgene is a biopharmaceutical company that develops innovative therapies to treat cancer and immune-inflammatory related diseases.
Celgene Corporation Earnings Preview Cheat Sheet.
Wall St. Earnings Expectations: The average estimate of analysts is for net income of 95 cents per share, a rise of 46.2% from the company’s actual earnings for the same quarter a year ago. During the past three months, the average estimate has moved up from 85 cents. Between one and three months ago, the average estimate moved up. It has dropped from $1 during the last month. For the year, analysts are projecting profit of $3.33 per share, a rise of 36.5% from last year.
Past Earnings Performance: The company is looking to make a streak of three quarters of beating estimates. Last quarter, it beat expectations by reporting net income of 97 cents per share, and the previous quarter, it had profit of 78 cents.
Investing Insights: Will the iPad 3 Be the Next Catalyst for Apple’s Stock?
Wall St. Revenue Expectations: Analysts are projecting a rise of 20.6% in revenue from the year-earlier quarter to $1.29 billion.
Analyst Ratings: Analysts are bullish on this stock with 22 analysts rating it as a buy, one rating it as a sell and four rating it as a hold.
A Look Back: In the third quarter, profit rose 32.7% to $373 million (81 cents a share) from $281.2 million (60 cents a share) the year earlier, exceeding analyst expectations. Revenue rose 37.3% to $1.25 billion from $910.1 million.
The company has enjoyed double-digit year-over-year percentage revenue growth for the past four quarters. Over that span, the company has averaged growth of 39.8%, with the biggest boost coming in the first quarter when revenue rose 42.2% from the year earlier quarter.
The company has seen net income rise in three straight quarters. Net income rose 79.8% in the second quarter and 9% in the first quarter.
Competitors to Watch: Novartis AG (NYSE:NVS), SuperGen, Inc. (NASDAQ:SUPG), Pfizer Inc. (NYSE:PFE), GlaxoSmithKline plc (NYSE:GSK), Bristol Myers Squibb Co. (NYSE:BMY), Genzyme Corporation (NASDAQ:GENZ), Cell Therapeutics, Inc. (NASDAQ:CTIC), Merck & Co., Inc. (NYSE:MRK), Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI), and Sanofi-Aventis SA (NYSE:SNY).
Stock Price Performance: During November 21, 2011 to January 20, 2012, the stock price had risen $12.52 (20.4%) from $61.32 to $73.84. The stock price saw one of its best stretches over the last year between December 14, 2011 and December 27, 2011 when shares rose for nine-straight days, rising 7.9% (+$4.98) over that span. It saw one of its worst periods between November 15, 2011 and November 21, 2011 when shares fell for five-straight days, falling 6.3% (-$4.09) over that span.
(Company fundamentals by Xignite Financials. Earnings estimates provided by Zacks)
Investing Insights: Here’s Why Chipotle’s Stock Keeps Winning.
To contact the reporter on this story: Derek Hoffman at email@example.com
To contact the editor responsible for this story: Damien Hoffman at firstname.lastname@example.org